|
CA2226575C
(en)
|
1995-07-27 |
2011-10-18 |
Genentech, Inc. |
Stabile isotonic lyophilized protein formulation
|
|
US6624142B2
(en)
|
1997-12-30 |
2003-09-23 |
Enzon, Inc. |
Trimethyl lock based tetrapartate prodrugs
|
|
CN1169573C
(zh)
|
1998-09-28 |
2004-10-06 |
参天制药株式会社 |
用于治疗角结膜障碍的、包含作为活性组分的钠尿肽的泪液分泌促进剂或滴眼剂
|
|
AR024558A1
(es)
|
1999-06-01 |
2002-10-16 |
Neuralab Ltd |
Composiciones del peptido a-beta y procesos para producir las mismas
|
|
BRPI0203172B8
(pt)
|
2001-09-28 |
2021-05-25 |
Nakao Kazuwa |
composição farmacêutica para acondroplasia
|
|
EP2042196B1
(en)
|
2001-10-10 |
2016-07-13 |
ratiopharm GmbH |
Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
|
|
US7122189B2
(en)
|
2002-08-13 |
2006-10-17 |
Enzon, Inc. |
Releasable polymeric conjugates based on aliphatic biodegradable linkers
|
|
AU2003297583B2
(en)
|
2002-11-26 |
2010-01-14 |
Biocon, Ltd |
Modified naturetic compounds, conjugates, and uses thereof
|
|
US7332164B2
(en)
|
2003-03-21 |
2008-02-19 |
Enzon Pharmaceuticals, Inc. |
Heterobifunctional polymeric bioconjugates
|
|
CA2521784C
(en)
|
2003-04-08 |
2012-03-27 |
Yeda Research And Development Co. Ltd. |
Reversible pegylated drugs
|
|
CA2763817C
(en)
|
2003-04-08 |
2014-05-27 |
Yeda Research And Development Co. Ltd. |
Reversible pegylated drugs
|
|
MXPA06010782A
(es)
|
2004-03-23 |
2007-03-28 |
Complex Biosystems Gmbh |
Ligador de profarmaco.
|
|
GB2427360A
(en)
|
2005-06-22 |
2006-12-27 |
Complex Biosystems Gmbh |
Aliphatic prodrug linker
|
|
CU23556A1
(es)
|
2005-11-30 |
2010-07-20 |
Ct Ingenieria Genetica Biotech |
Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
|
|
US8450269B2
(en)
|
2006-02-03 |
2013-05-28 |
Prolor Biotech Ltd. |
Long-acting growth hormone and methods of producing same
|
|
US9283260B2
(en)
|
2006-04-21 |
2016-03-15 |
Amgen Inc. |
Lyophilized therapeutic peptibody formulations
|
|
US20100047258A1
(en)
*
|
2006-08-02 |
2010-02-25 |
Dong Wang |
Drug Carriers, Their Synthesis, and Methods of Use Thereof
|
|
JP2010502231A
(ja)
*
|
2006-09-08 |
2010-01-28 |
メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ |
血管拡張作用を欠く水利尿およびナトリウム利尿ポリペプチド
|
|
JP2010503707A
(ja)
|
2006-09-15 |
2010-02-04 |
エンゾン ファーマスーティカルズ インコーポレイテッド |
オリゴヌクレオチドの送達を目的としたヒンダードエステル系生体分解性リンカー
|
|
TWI409081B
(zh)
|
2006-11-09 |
2013-09-21 |
Alcon Res Ltd |
用於藥物輸送之水不溶性聚合物基質
|
|
CA2681567C
(en)
|
2007-03-22 |
2016-07-19 |
The Regents Of The University Of Colorado, A Body Corporate |
Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
|
|
KR20080098216A
(ko)
|
2007-05-04 |
2008-11-07 |
한미약품 주식회사 |
캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
|
|
ATE502114T1
(de)
|
2007-06-21 |
2011-04-15 |
Univ Muenchen Tech |
Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
|
|
TW200922624A
(en)
|
2007-07-11 |
2009-06-01 |
Enzon Pharmaceuticals Inc |
Polymeric drug delivery system containing a multi-substituted aromatic moiety
|
|
AR069409A1
(es)
*
|
2007-11-21 |
2010-01-20 |
Biomarin Pharm Inc |
Variantes de peptidos natriureticos de tipo c
|
|
AU2008340304B2
(en)
|
2007-12-21 |
2016-03-03 |
Aptevo Biotherapeutics Llc |
Stabilized factor IX formulations containing trehalose
|
|
MX2010008024A
(es)
|
2008-02-01 |
2010-12-21 |
Ascendis Pharma As |
Profarmaco que comprende un enlazador que se puede separar por si mismo.
|
|
TW201004648A
(en)
|
2008-05-23 |
2010-02-01 |
Enzon Pharmaceuticals Inc |
Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
|
|
WO2009156481A1
(en)
|
2008-06-25 |
2009-12-30 |
Ascendis Pharma As |
Pegylated bnp
|
|
WO2010033216A1
(en)
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Polymer conjugates of nesiritide peptides
|
|
CA2748314C
(en)
|
2009-02-03 |
2018-10-02 |
Amunix Operating Inc. |
Extended recombinant polypeptides and compositions comprising same
|
|
ES2608457T3
(es)
*
|
2009-05-20 |
2017-04-11 |
Biomarin Pharmaceutical Inc. |
Variantes de péptido natriurético de tipo C
|
|
EP2459227B1
(en)
|
2009-07-31 |
2021-03-17 |
Ascendis Pharma A/S |
Prodrugs containing an aromatic amine connected by an amide bond to a carrier
|
|
WO2011031441A1
(en)
|
2009-08-28 |
2011-03-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Therapy with a chimeric molecule and a pro-apoptotic agent
|
|
CA2783296C
(en)
|
2009-12-15 |
2019-01-15 |
Ascendis Pharma As |
Growth hormone composition
|
|
WO2011075471A2
(en)
|
2009-12-18 |
2011-06-23 |
Alcon Research, Ltd. |
Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders
|
|
CN102724967A
(zh)
|
2009-12-31 |
2012-10-10 |
安龙制药公司 |
包括可释放的脲连接体的含芳香胺化合物的聚合缀合物
|
|
WO2011089215A1
(en)
|
2010-01-22 |
2011-07-28 |
Ascendis Pharma As |
Dipeptide-based prodrug linkers for aromatic amine-containing drugs
|
|
EP2525830B1
(en)
|
2010-01-22 |
2016-05-11 |
Ascendis Pharma A/S |
Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
|
|
WO2011089214A1
(en)
|
2010-01-22 |
2011-07-28 |
Ascendis Pharma As |
Carrier-linked carbamate prodrug linkers
|
|
EP2552967A4
(en)
|
2010-04-02 |
2014-10-08 |
Amunix Operating Inc |
BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
|
|
EP2566334B1
(en)
|
2010-05-05 |
2018-04-18 |
Prolynx, LLC |
Controlled drug release from solid supports
|
|
EP2566335B1
(en)
|
2010-05-05 |
2016-06-29 |
Prolynx Llc |
Controlled release of active compounds from macromolecular conjugates
|
|
WO2011144756A1
(en)
|
2010-05-21 |
2011-11-24 |
Xl-Protein Gmbh |
Biosynthetic proline/alanine random coil polypeptides and their uses
|
|
WO2013024047A1
(en)
|
2011-08-12 |
2013-02-21 |
Ascendis Pharma A/S |
High-loading water-soluble carrier-linked prodrugs
|
|
MX349950B
(es)
|
2011-08-12 |
2017-08-22 |
Ascendis Pharma As |
Profarmacos de treprostinil enlazados a un portador.
|
|
AU2012296951B2
(en)
|
2011-08-12 |
2016-09-15 |
Ascendis Pharma A/S |
Protein carrier-linked prodrugs
|
|
AU2012296950B2
(en)
|
2011-08-12 |
2016-09-22 |
Ascendis Pharma A/S |
Polymeric hyperbranched carrier-linked prodrugs
|
|
HK1198913A1
(en)
|
2011-08-12 |
2015-06-19 |
Ascendis Pharma A/S |
Carrier-linked prodrugs having reversible carboxylic ester linkages
|
|
WO2013036857A1
(en)
|
2011-09-07 |
2013-03-14 |
Prolynx Llc |
Sulfone linkers
|
|
US20150087688A1
(en)
|
2012-04-25 |
2015-03-26 |
Ascendis Pharma A/S |
Prodrugs of hydroxyl-comprising drugs
|
|
JPWO2013161895A1
(ja)
*
|
2012-04-25 |
2015-12-24 |
第一三共株式会社 |
骨修復促進剤
|
|
US10052366B2
(en)
|
2012-05-21 |
2018-08-21 |
Alexion Pharmaceuticsl, Inc. |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
|
JP6536871B2
(ja)
|
2013-12-02 |
2019-07-03 |
国立大学法人京都大学 |
Ｆｇｆｒ３病の予防および治療剤ならびにそのスクリーニング方法
|
|
KR20160118264A
(ko)
|
2014-02-27 |
2016-10-11 |
다이이찌 산쿄 가부시키가이샤 |
스테로이드제 투여로 유발되는 성장 장해에 대한 의약
|
|
US11547743B2
(en)
|
2014-04-28 |
2023-01-10 |
Eisai R&D Management Co., Ltd. |
Lyophilized formulation of HGF
|
|
CA2955569C
(en)
|
2014-08-06 |
2023-02-14 |
Ascendis Pharma A/S |
Prodrugs comprising an aminoalkyl glycine linker
|
|
EP3242689A1
(en)
|
2015-01-09 |
2017-11-15 |
Ascendis Pharma Growth Disorders A/S |
Cnp prodrugs
|
|
KR20260046164A
(ko)
|
2015-07-30 |
2026-04-06 |
바이오마린 파머수티컬 인크. |
골 이형성증 치료를 위한 c―형 나트륨이뇨 펩타이드 변이체의 용도
|
|
PL3386531T3
(pl)
|
2015-12-08 |
2022-02-28 |
Biomarin Pharmaceutical Inc. |
Zastosowanie wariantów peptydu natriuretycznego typu c w leczeniu choroby zwyrodnieniowej stawów
|
|
WO2017118707A1
(en)
|
2016-01-08 |
2017-07-13 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release cnp agonists with reduced side-effects
|
|
LT3400019T
(lt)
|
2016-01-08 |
2022-12-12 |
Ascendis Pharma Growth Disorders A/S |
Cnp provaistai su prie žiedo fragmento prijungtu nešikliu
|
|
IL259827B2
(en)
|
2016-01-08 |
2025-07-01 |
Ascendis Pharma Growth Disorders As |
Controlled-release CNP agonists with low initial NPR-B activity
|
|
IL297375B2
(en)
|
2016-01-08 |
2024-02-01 |
Ascendis Pharma Growth Disorders As |
Controlled-release CNP agonists with low NPR–C binding
|
|
MX2018008061A
(es)
|
2016-01-08 |
2018-08-23 |
Ascendis Pharma Growth Disorders As |
Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.
|
|
NZ743487A
(en)
|
2016-01-08 |
2023-02-24 |
Ascendis Pharma Growth Disorders As |
Controlled-release cnp agonists with increased nep stability
|
|
HUE062117T2
(hu)
|
2016-09-29 |
2023-09-28 |
Ascendis Pharma Growth Disorders As |
Kombinációs terápia szabályozott felszabadulású CNP agonistákkal
|
|
CA3109223A1
(en)
|
2018-08-16 |
2020-02-20 |
Beyondspring Pharmaceuticals, Inc. |
Method and composition for stimulating immune response
|
|
EP3923906A1
(en)
|
2019-02-11 |
2021-12-22 |
Ascendis Pharma Growth Disorders A/S |
Dry pharmaceutical formulations of cnp conjugates
|